Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FOLDNASDAQ:KRTXNASDAQ:RARXNASDAQ:THORNASDAQ:ZGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFOLDAmicus Therapeutics$5.73-3.4%$6.26$5.51▼$12.65$1.83B0.543.13 million shs5.47 million shsKRTXKaruna Therapeutics$329.83$327.01$158.38▼$329.99$12.58B1.18832,048 shs5 shsRARXRa Pharmaceuticals$47.99$47.99$19.64▼$48.02$2.27B1.051.16 million shs30,200 shsTHORSynthorx$67.99$67.99$11.05▼$71.90$2.20BN/A474,507 shsN/AZGNXZogenix$26.68$26.52$11.03▼$26.90$1.50B0.893.76 million shs94 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFOLDAmicus Therapeutics0.00%+5.14%-2.95%-27.33%-40.22%KRTXKaruna Therapeutics0.00%0.00%0.00%0.00%0.00%RARXRa Pharmaceuticals0.00%0.00%0.00%0.00%0.00%THORSynthorx0.00%0.00%0.00%0.00%0.00%ZGNXZogenix0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFOLDAmicus Therapeutics3.895 of 5 stars3.41.00.04.31.90.01.9KRTXKaruna TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARARXRa PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATHORSynthorxN/AN/AN/AN/AN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFOLDAmicus Therapeutics 2.70Moderate Buy$16.22183.11% UpsideKRTXKaruna Therapeutics 0.00N/AN/AN/ARARXRa Pharmaceuticals 0.00N/AN/AN/ATHORSynthorx 0.00N/AN/AN/AZGNXZogenix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest FOLD, ZGNX, KRTX, RARX, and THOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025FOLDAmicus TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.005/2/2025FOLDAmicus TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $9.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFOLDAmicus Therapeutics$528.29M3.34N/AN/A$0.65 per share8.82KRTXKaruna Therapeutics$654K19,239.07N/AN/A$33.24 per share9.92RARXRa Pharmaceuticals$3M757.11N/AN/A$5.56 per share8.63THORSynthorxN/AN/AN/AN/A$6.72 per shareN/AZGNXZogenix$81.69M18.36N/AN/A$6.64 per share4.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFOLDAmicus Therapeutics-$56.11M-$0.09N/A13.33N/A-5.41%4.67%1.05%8/14/2025 (Estimated)KRTXKaruna Therapeutics-$433.68M-$11.72N/AN/AN/AN/A-31.63%-30.38%N/ARARXRa Pharmaceuticals-$102.69M-$2.31N/AN/AN/AN/A-44.61%-41.60%N/ATHORSynthorx-$56.61M-$6.59N/AN/AN/AN/A-26.09%-24.62%N/AZGNXZogenix-$209.38M-$4.07N/AN/AN/A-278.38%-91.20%-43.60%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AKRTXKaruna TherapeuticsN/AN/AN/AN/AN/ARARXRa PharmaceuticalsN/AN/AN/AN/AN/ATHORSynthorxN/AN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFOLDAmicus Therapeutics2.023.342.47KRTXKaruna TherapeuticsN/A19.3119.31RARXRa Pharmaceuticals0.0114.7814.79THORSynthorxN/A18.8718.87ZGNXZogenix0.883.634.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFOLDAmicus TherapeuticsN/AKRTXKaruna TherapeuticsN/ARARXRa PharmaceuticalsN/ATHORSynthorx66.12%ZGNXZogenixN/AInsider OwnershipCompanyInsider OwnershipFOLDAmicus Therapeutics2.20%KRTXKaruna Therapeutics13.20%RARXRa Pharmaceuticals4.30%THORSynthorx53.20%ZGNXZogenix4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFOLDAmicus Therapeutics480307.93 million301.16 millionOptionableKRTXKaruna Therapeutics33938.15 million33.16 millionOptionableRARXRa Pharmaceuticals7247.33 millionN/AOptionableTHORSynthorx4832.34 millionN/ANot OptionableZGNXZogenix21856.23 million53.92 millionOptionableFOLD, ZGNX, KRTX, RARX, and THOR HeadlinesRecent News About These CompaniesAfter epilepsy setback, Zogenix buys Modis and rare disease drug for $400mJanuary 2, 2025 | pharmaphorum.comPNeedle-Free Drug Injection Systems Business Analysis Report 2023-2030 Featuring AKRA Dermojet, Crossject, D`Antonio Consultants, PharmaJet, and ZogenixAugust 1, 2024 | globenewswire.comHwasung Industrial Co Ltd 002460March 23, 2024 | morningstar.comMOrally Inhaled DihydroergotamineFebruary 13, 2024 | medscape.comMMRI in HeadacheAugust 25, 2023 | medscape.comMKratom: What We KnowAugust 13, 2023 | medscape.comMAlcon (NYSE: ALC)July 6, 2023 | fool.comLongeveron Inc Ordinary Shares - Class AMay 20, 2023 | morningstar.comMDravet Syndrome Market Report 2032: Epidemiology Data, Pipeline ... - Digital JournalMay 10, 2023 | news.google.comNGlobal Needle Free Diabetes Management Market Size 2023 ... - The Northwestern ExaminerMay 8, 2023 | news.google.comNGlobal Needle-Free Drug Delivery Systems Market New ... - The Northwestern ExaminerMay 8, 2023 | news.google.comNNeedle Free Injection Systems Market Size Reach Valuation of USD 519.3 Million in 2030 - Emergen Research - openPRMay 4, 2023 | news.google.comNNeedle Free Diabetes Management Market Forecast 2023 – 2032 ... - Taiwan NewsApril 28, 2023 | news.google.comNThe Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine HeadacheApril 25, 2023 | medscape.comMLong-Acting Injectable Antipsychotics Market 2023-2033: Global ... - Taiwan NewsApril 24, 2023 | news.google.comNAnti-epileptic Drugs Market Expected to Expand at a Steady 2023 ... - Digital JournalApril 24, 2023 | news.google.comNDravet Syndrome Pipeline Assessment (2023 Updates) | In-depth ... - Digital JournalApril 19, 2023 | news.google.comNForm SC 14D9/A Provention Bio, Inc. Filed by: Provention Bio, Inc. - StreetInsider.comApril 19, 2023 | news.google.comNDEA lifts Dravet therapy Fintepla's controlled substance status |... - Dravet Syndrome NewsApril 18, 2023 | news.google.comNUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - Longview News-JournalApril 17, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFOLD, ZGNX, KRTX, RARX, and THOR Company DescriptionsAmicus Therapeutics NASDAQ:FOLD$5.73 -0.20 (-3.37%) As of 04:00 PM EasternAmicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Karuna Therapeutics NASDAQ:KRTXKaruna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Ra Pharmaceuticals NASDAQ:RARXRa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.Synthorx NASDAQ:THORSynthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.Zogenix NASDAQ:ZGNXZogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.